A 52-year-old man with newly diagnosed type 2 diabetes mellitus undergoes a 72-hour fasting study. Plasma glucose is 180 mg/dL, and serum C-peptide is detectable but low. Which finding best distinguishes his metabolic state from that of a patient with type 1 diabetes mellitus under the same fasting conditions?

Explanation

## Distinguishing Type 2 from Type 1 DM: The C-Peptide Marker **Key Point:** The **presence of detectable C-peptide and residual endogenous insulin secretion in type 2 DM vs. complete absence in type 1 DM** is the single best discriminator between the two conditions, especially during fasting when exogenous insulin is not being administered. ### Pathophysiologic Basis | Feature | Type 1 DM | Type 2 DM | |---|---|---| | **Pancreatic β-cell status** | Autoimmune destruction; absent | Insulin resistance + progressive β-cell dysfunction; residual function | | **C-peptide (fasting)** | Undetectable (<0.5 ng/mL) | Detectable (often normal or elevated early) | | **Endogenous insulin** | None | Present but insufficient for glucose control | | **Glucagon response** | Often exaggerated (loss of inhibition) | May be relatively normal or blunted | | **Lipolysis** | Unopposed → ↑↑ FFA, ketones | Partially suppressed by residual insulin | | **DKA risk** | High (even with modest hyperglycemia) | Low (unless severe stress) | **High-Yield:** C-peptide is cleaved from proinsulin during insulin secretion in a 1:1 molar ratio. Unlike insulin, C-peptide is not extracted by the liver and is not affected by exogenous insulin therapy. Therefore: - **Detectable C-peptide = endogenous insulin secretion is occurring** - **Undetectable C-peptide = no endogenous insulin production** This makes C-peptide the gold standard for distinguishing residual β-cell function in type 2 DM from the complete loss in type 1 DM. **Clinical Pearl:** In type 2 DM, fasting C-peptide may even be *elevated* early in the disease due to compensatory hyperinsulinemia in response to insulin resistance. Over time, β-cell exhaustion occurs, and C-peptide declines—but it rarely becomes completely undetectable unless the patient has had diabetes for many decades or develops autoimmune β-cell destruction (LADA, latent autoimmune diabetes in adults). ### Why Other Options Are Inferior - **Option 0 (Glucagon levels):** While glucagon is often exaggerated in type 1 DM due to loss of insulin's inhibitory effect on α-cells, glucagon levels can overlap between the two conditions and are not as reliable or specific as C-peptide measurement. - **Option 2 (FFA and ketones):** Type 1 DM does have higher lipolysis and ketone production, but this is a *consequence* of insulin deficiency, not a direct discriminator. Type 2 patients can also develop elevated FFA and ketones under severe stress (e.g., infection, DKA in rare cases). - **Option 3 (Hyperglycemia alone):** Both conditions present with elevated fasting glucose; hyperglycemia is not discriminatory. **Mnemonic:** **C-peptide = Clue to endogenous insulin production**. If C-peptide is present, the pancreas is still making insulin (type 2 or LADA); if absent, the pancreas has failed (type 1). [cite:Harrison 21e Ch 417]